Observational Study

**Presence of c.3956delC mutation in familial adenomatous polyposis patients from Brazil**

Caroline Aquino Moreira-Nunes, Diego di Felipe Ávila Alcântara, Sérgio Figueiredo Lima-Júnior, Sandro Roberto de Araújo Cavalléro, Juan Antonio Rey, Giovanny Rebouças Pinto, Paulo Pimentel de Assumpção, Rommel Rodríguez Burbano

Caroline Aquino Moreira-Nunes, Diego di Felipe Ávila Alcântara, Rommel Rodríguez Burbano, Biological Science Institute, Federal University of Pará, Belém 66075110, Brazil

Sérgio Figueiredo Lima-Júnior, Sandro Roberto de Araújo Cavalléro, Paulo Pimentel de Assumpção, Nucleus of Research in Oncology, Federal University of Pará, Belém 66073000, Brazil

Juan Antonio Rey, Molecular Neuro-oncogenetics Laboratory, Research Unit-Unitidad de Investigación, Hospital Universitario La Paz, 28046 Madrid, Spain

Giovanny Rebouças Pinto, Genetics and Molecular Biology Laboratory, Federal University of Piauí, Parnaíba 64049-550, Brazil

Author contributions: Moreira-Nunes CA and Alcântara DFA contributed equally to this work; Moreira-Nunes CA, Alcântara DFA, Lima-Júnior SF, Cavalléro SRA, Pinto GR, Rey JA, Assumpção PP and Burbano RR conceived and designed the experiments; Moreira-Nunes CA, Alcântara DFA, Lima-Júnior SF and Cavalléro SRA performed the experiments; Moreira-Nunes CA, Alcântara DFA, Rey JA, Assumpção PP and Burbano RR analyzed the data; Moreira-Nunes CA, Alcântara DFA, Pinto GR and Burbano RR wrote the paper; all authors read and approved the final manuscript.

Supported by Grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (www.cnpq.br), No. 401976/2010-6 and No. 305220/2013-6 (to Burbano RR); and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (www.capes.gov.br), No. PNPD 2810/2011 (to Moreira-Nunes CA).

Institutional review board statement: The study was approved by the Research Ethics Committee of the João de Barros Barreto University Hospital (Belém, Pará, Brazil), approval number: 274/12.

Informed consent statement: All analyzed patients or their guardians signed a consent form, and it was assured that the use of biological material and study participation would not be harmful or negatively influence the patients’ treatment.

Conflict-of-interest statement: The authors have no conflicts of interest to declare. The funders of this study had no role in study design, data collection/analysis, publication decisions, or manuscript preparation.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Caroline Aquino Moreira-Nunes, PhD, Post-doctoral Research Fellow, Biological Science Institute, Federal University of Pará. Augusto Correa Street 01, Belém 66075110, Brazil. caroline@ufpa.br

Telephone: +559-182285161

Fax: +559-132017102

Received: July 24, 2014

Peer-review started: July 25, 2014

First decision: September 3, 2014

Revised: May 21, 2015

Accepted: June 16, 2015

Article in press: June 16, 2015

Published online: August 21, 2015

**Abstract**

**AIM:** To characterize *APC* gene mutations and correlate them with patient phenotypes in individuals diagnosed with familial adenomatous polyposis (FAP) in Brazil. We report the presence of a unique c.3956delC mutation in 17 FAP patients, which caused a premature stop codon at amino acid position 1320 (p.Thr1320X).

**Background:** FAP is a hereditary autosomal dominant disease with high penetrance and variable expressivity. The adenomatous polyposis coli (APC) gene, located on chromosome 5q21, is the major gene in the FAP susceptibility. A wide spectrum of mutations has been reported in the *APC* gene, leading to different phenotypes.

**Methods:** We performed direct sequencing of *APC* exons and intron-exon boundaries in 53 FAP patients from Brazil (54% men, 46% women; median age of 43 years; age range: 25-80 years). A cDNA analysis was performed to determine the effect of the c.3956delC mutation on the APC protein.

**Results:** Among the 53 FAP patients, we found 17 individuals with the c.3956delC mutation. This missense mutation led to a premature stop codon (p.Thr1320X) in the APC protein, resulting in protein truncation.

**Conclusion:** The presence of the c.3956delC mutation in FAP patients from Brazil indicates a high frequency of this mutation in the Brazilian population. This finding suggests the need for increased genetic counseling and surveillance programs to prevent colorectal cancer in individuals with FAP.
with familial adenomatous polyposis (FAP) in northern Brazil.

**METHODS:** A total of 15 individuals diagnosed with FAP from 5 different families from the north of Brazil were analyzed in this study. In addition to patients with histopathological diagnosis of FAP, family members who had not developed the disease were also tested in order to identify mutations and for possible genetic counseling. All analyzed patients or their guardians signed a consent form approved by the Research Ethics Committee of the João de Barros Barreto University Hospital (Belem, Brazil). DNA extracted from the peripheral blood of a member of each of the affected families was subjected to direct sequencing. The proband of each family was sequenced to identify germline mutations using the Ion Torrent platform. To validate the detected mutations, Sanger sequencing was also performed. The samples from all patients were also tested for the identification of mutations by real-time quantitative polymerase chain reaction using the amplification refractory mutation system.

**RESULTS:** Through interviews with relatives and a search of medical records, it was possible to construct genograms for three of the five families included in the study. All 15 patients from the five families with FAP exhibited mutations in the APC gene, and all mutations were detected in exon 15 of the APC gene. In addition to the patients with a histological diagnosis of FAP, family members without disease symptoms showed the mutation in the APC gene. In the present study, we detected two of the three most frequent germline mutations in the literature: the mutation at codon 1309 and the mutation at codon 1061. The presence of c.3956delC mutation was found in all families from this study, and suggests that this mutation was introduced in the population of the State of Pará through ancestor immigration (i.e., a de novo mutation that arose in one member belonging to this state from Brazil).

**CONCLUSION:** Regardless of its origin, the c.3956delC mutation is a strong candidate biomarker of this hereditary cancer syndrome in families of northern Brazil.

**Key words:** Familial adenomatous polyposis; APC; Torrent sequencing; Colorectal cancer

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In the northern region of Brazil, gastrointestinal tumors are the second most frequent type of cancer among men and the third most frequent among women. These tumors are considered a serious public health problem because they are often diagnosed in advanced stages and have extremely low survival rates. Evaluation of family history to determine the number of relatives affected and genetic screening analysis are important preventive measures to assist in the early diagnosis of patients who have not yet developed the disease, as was the case of some patients analyzed in this study.

Moreira-Nunes CA, Alcântara DFA, Lima-Júnior SF, Cavalléro SRA, Rey JA, Pinto GR, Assumpção PP, Burbano RR. Presence of c.3956delC mutation in familial adenomatous polyposis patients from Brazil. *World J Gastroenterol* 2015; 21(31): 9413-9419 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i31/9413.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i31.9413

**INTRODUCTION**

Familial adenomatous polyposis (FAP) is a hereditary cancer predisposition syndrome with autosomal dominant inheritance caused by germline mutations, mainly in the adenomatous polyposis coli (APC) gene. The main clinical feature of FAP is the development, in the second and third decades of life, of multiple (hundreds to thousands) adenomatous polyps in the colon with the capacity for malignant transformation[4-8].

The tumor suppressor gene APC, located on chromosome 5q21, has 16 exons and encodes a 300-kDa protein that participates in the Wnt signaling pathway, which is important in signal transduction and the control of apoptosis[4-6]. APC gene inactivation occurs through allelic loss, primarily through mutations, which generally produces a truncated protein lacking the carboxyl-terminal region and loss of function[7,8].

To date, 858 different mutations in the APC gene have been recorded in the Human Gene Mutation Database (HGMD). Twenty-three percent of the germline alterations of this gene occur between codons 1055 and 1309. The three most common germline mutations are the deletion of 5 base pairs (bp) from codons 1309 and 1061 and the deletion of 4 bp from codon 1064[9].

The FAP phenotype (number of polyps and disease aggressiveness) can be predicted from the APC gene mutation. The FAP phenotypes can be defined as the following: (1) severe/profuse, for mutations located between codons 1250 and 1464; (2) intermediate, for mutations located between codons 158 and 1595, except for mutations located between codons 312 and 412 and for mutations located between codons 1250 and 1464; and (3) attenuated, for mutations located in exon 9 and near the 5' and 3' ends of the APC gene[10-16].

In the north and northeast regions of Brazil, gastrointestinal tumors are the second most frequent type of cancer among men and the third most frequent among women. These tumors are considered a serious public health problem because they are often diagnosed in advanced stages and have extremely low
survival rates\textsuperscript{[17]}. The aim of this study was to characterize the mutations present in the \textit{APC} gene, correlate them with patient phenotypes, and evaluate genomic alterations in individuals diagnosed with FAP in northern Brazil.

**MATERIALS AND METHODS**

**Ethics statement**

The study was approved by the Research Ethics Committee of the João de Barros Barreto University Hospital (Belém, Pará, Brazil; approval number: 274/12). All analyzed patients or their guardians signed a consent form, and it was assured that the use of biological material and study participation would not be harmful or negatively influence the patients’ treatment.

**Patients**

A total of 15 patients belonging to 5 different families were analyzed in this study (Table 1). All patients resided in the State of Pará and were assisted at the Coloproctology Outpatient Clinic of the João de Barros Barreto University Hospital (Belém, Pará, Brazil). Peripheral blood samples were collected from all individuals for analysis.

In addition to patients with histopathological diagnosis of FAP, family members who had not developed the disease were also tested to identify mutations and for possible genetic counseling in the same manner as provided to members of the FAP2 and FAP3 families (Table 1).

**DNA extraction**

Genomic DNA was extracted from human peripheral blood samples using the QIAamp DNA Blood Kit (Qiagen\textsuperscript{®}), following the manufacturer’s instructions.

**Sequencing the APC gene**

The DNA extracted from the peripheral blood of a member of each of the affected families was subjected to direct sequencing.

Direct sequencing of all exons of the \textit{APC} gene (NM_000038.5) was performed by the next-generation sequencing platform Ion Torrent™ (Life Technologies™), following the Ion AmpliSeq™ Library Preparation methodology (Life Technologies™).

The primers for detection of changes in the nucleotide sequence of the gene were designed through the Ion Torrent™ platform using the Ion AmpliSeq Designer software (available at: https://www.ampliseq.com).

Analysis of the sequenced data was performed using the analysis software available in the Ion Torrent™ platform.

**Sanger sequencing**

To validate the detected mutations, Sanger sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit. After ethanol purification, the samples were run on an ABI 3730 sequencer. The chromatogram of the Sanger sequencing results was analyzed using Sequencing Analysis vs 5.2 Program (Applied Biosystem, United States).

**RESULTS**

Through interviews with relatives and a search of medical records, it was possible to construct genograms for three of the five families included in the study - FAP1, FAP2, and FAP3 - which, coincidentally, are the families with the largest number of individuals affected by the disease in subsequent generations (Figure 1). The genealogical analysis of the remaining two families was not possible due to a lack of information from patients regarding their relatives.

All 15 patients from the five families with FAP exhibited mutations in the \textit{APC} gene, and all mutations were detected in exon 15 of the \textit{APC} gene. The presence of c.3956delC mutation was found in all families from this study. In addition to the patients with a histological diagnosis of FAP, family members without disease symptoms showed the mutation in the \textit{APC} gene (Table 2).

**DISCUSSION**

FAP is caused by germline mutations primarily in the \textit{APC} gene and shows autosomal dominant inheritance. The main clinical feature of the disease is the deve-

Table 1  Patients analyzed in the study

| Patients | Gender | Age at diagnosis | Histopathology |
|----------|--------|-----------------|----------------|
| Family 1 (FAP1) | | | |
| 01A | Female | 23 | FAP |
| 01B | Female | 25 | FAP |
| 01C | Female | 18 | FAP |
| 01D | Male | 14 | FAP |
| 01E | Male | 17 | FAP |
| Family 2 (FAP2) | | | |
| 02F | Female | 40 | FAP |
| 02G | Male | 1 | FAP |
| 02H | Female | 15 | FAP |
| 02I | Male | NA\textsuperscript{2} | - |
| Family 3 (FAP3) | | | |
| 03J | Male | 30 | FAP |
| 03H | Female | NA | - |
| 03L | Female | NA | - |
| 03M | Female | NA | - |
| Family 4 (FAP4) | | | |
| 04N | Male | 40 | FAP |
| Family 5 (FAP5) | | | |
| 05O | Male | 25 | FAP |

\textsuperscript{1}Unknown; \textsuperscript{2}Patients without disease. FAP: Familial adenomatous polyposis; NA: Not applicable.
For mutations in the APC gene.

In the present study, we detected two of the three most frequent germline mutations: the mutation at codon 1309 (found in the FAP2 and FAP5 families) and the mutation at codon 1061 (found in the FAP1 family). Half et al. [2] found an association between the mutation at codon 1309 and 10% of patients with FAP in the literature, which is in agreement with the study by Torrezan et al. [27], who identified this mutation in 9% of the 23 families with FAP in southeastern Brazil. In the present study, the mutation at codon 1309 occurred in all patients with FAP. This frequency is higher than the global average, and, for this reason, we are currently increasing the sample size of families with FAP to assess the validity of this frequency.

The mutation at codon 1061 affects 5% of patients in the literature, according to the survey performed by literature reports reveal that most mutations found in FAP (≥ 60%) are located in the central region of the protein (between codons 1281-1556), the so-called "mutation cluster region" (MCR). The MCR corresponds to the region of the APC gene encoding the protein domain responsible for β-catenin regulation [20,23-25]. Mutations that occur in this region generally produce a truncated protein responsible for an increase in the free pool of β-catenin, which is transported to the nucleus, thus activating the transcription of genes involved in cell proliferation [26]. In this study, all mutations discovered in the families with FAP occurred in the MCR region, confirming this region as a hotspot for mutations in the APC gene.

In the present study, we detected two of the three most frequent germline mutations: the mutation at codon 1309 (found in the FAP2 and FAP5 families) and the mutation at codon 1061 (found in the FAP1 family). Half et al. [21] found an association between the mutation at codon 1309 and 10% of patients with FAP in the literature, which is in agreement with the study by Torrezan et al. [27], who identified this mutation in 9% of the 23 families with FAP in southeastern Brazil. In the present study, the mutation at codon 1309 occurred in all patients with FAP. This frequency is higher than the global average, and, for this reason, we are currently increasing the sample size of families with FAP to assess the validity of this frequency.

The mutation at codon 1061 affects 5% of patients in the literature, according to the survey performed by

Figure 1 Pedigrees of hereditary diffuse gastric cancer families. A: FAP1 - A family with eight affected members and the presence of APC mutations; B: FAP2 - a family with four affected members and the presence of APC mutations; C: FAP3 - a family with five affected members with APC mutations, and three members with no disease appearance, although with the presence of APC mutations. The numbers present under the symbols represent the age at diagnosis. The solid symbols represent the affected members with confirmed adenomatous polyposis diagnoses. Upper left arrows indicate the probands.
Half et al [1]. This mutation was found in 20% of the five families with FAP from the State of Pará analyzed in this study, although it was not detected in the studies with families from southeastern Brazil performed by Torrezan et al [27] and De Queiroz Rossanese et al [28]. This result reinforces the difference found between the types of APC gene alterations and the geographic region of Brazil to which the FAP patients belong.

FAP is caused by a highly heterogeneous spectrum of mutations, which are shared among patients from different families, as shown in this study [29,30]. In a comprehensive study performed in a Canadian population by Jarry et al [29], it was demonstrated that several families with FAP exhibited c.3183_3187delACAAA and c.3927_3931delAAAGA mutations, which were also described in this study.

Through direct sequencing of the APC gene, we identified the pathogenic mutation c.3956delC in all families analyzed in this study. This mutation, considered as a frameshift mutation type, and was not found in other Brazilian studies conducted with patients from southeastern Brazil [27,28]. This disparity demonstrates a difference in the spectrum of APC gene alterations in families with FAP according to the geographic region of Brazil. This phenomenon most likely occurs because of miscegenation-related ethnic differences between the populations of the south and north of Brazil [31,32].

Thus, the c.3956delC mutation proved to be an important cause of FAP in northern Brazil and results from a founder effect, most likely originating from Japanese communities, where this mutation was first described by Miyaki et al [33] in colorectal tumors from three unrelated families. To our knowledge, there are no reports describing the c.3956delC mutation in the germline of families with FAP, as shown in this study.

It is likely that either this germline mutation was introduced into the State of Pará after the 1929 landing of Japanese immigrants in Belém [33] or that c.3956delC is a de novo mutation that emerged in a member of the Pará population. Regardless of its origin, the c.3956delC mutation is a strong candidate biomarker for this hereditary cancer syndrome in families of northern Brazil.

According to Crabtree et al [34], the presence of a mutation in the MCR region confers to FAP the severe phenotype, regardless of the contribution of mutations characteristic of other phenotypes. In this study, this assumption held because all families with FAP had in common the presence of mutation at codon 1319, in the MCR region.

The genotype-phenotype relationship in FAP is a determining factor for clinical guidance and genetic counseling, as well as for simplifying the search for mutations in patients with FAP and their relatives [14,15,35].

The diagnosis of severe FAP in the study population occurred around the second and third decade of life, while intermediate FAP was diagnosed in the fourth decade of life. This timeline is in accordance with the guidelines for the clinical management of FAP published by Vasen et al [36], who demonstrated that the onset of the disease in patients with the severe form of FAP occurred, on average, 10 years before the onset in carriers of intermediate and attenuated forms. As an example, in this study the FAP1 family exhibited the early form of the disease, and one of the members had the syndrome diagnosed at 14 years of age, with the presence of thousands of polyps throughout the intestine. This aggressive phenotype is justified by the presence of the c.3956delC mutation, associated with the severe phenotype. For this reason, and in accordance with the abovementioned guidelines, clinical and diagnostic evaluations should be performed in all FAP family members, starting at the second decade of life.

In conclusion, the presence of the c.3956delC mutation in all families studied leads us to believe that this mutation was introduced in the population of the State of Pará through the immigration of ancestors (i.e., a de novo mutation that emerged in a member belonging to this State). Regardless of its origin, the c.3956delC mutation is a strong candidate biomarker of this hereditary cancer syndrome in families of northern Brazil.

It is noteworthy that different germline mutations were found in families of different ethnic groups. Therefore, there is a need to identify the alterations responsible for hereditary cancer syndromes in the Brazilian population, especially in populations of the northern and northeastern regions, where a high incidence of gastrointestinal tumors is observed.

Table 2 Mutations in the APC gene: Relationship between genotype and phenotype in patients with familial adenomatous polyposis

| Families | Exon | Codon | Mutation | Phenotype | Ref. |
|----------|------|-------|----------|-----------|-----|
| FAP1     | 15   | 1061  | c.3183_3187delACAAA | Intermediate | Ficari et al [37], Jarry et al [36] |
| FAP2     | 15   | 1309  | c.3927_3931delAAAGA | Severe | Miyoshi et al [38], Jarry et al [36] |
| FAP5     | 15   | 1309  | c.3921_3925delAAAAG | Severe | Miyaki et al [39], Mulkens et al [21] |
| FAP1-FAP5| 15   | 1319  | c.3956delC | Severe | Miyaki et al [21] |

1According to Nieuwenhuis et al [20].
Background
The main clinical feature of familial adenomatous polyposis (FAP) is the development, in the second and third decades of life, of multiple (hundreds to thousands) adenomatous polyps in the colon with the capacity for malignant transformation. It is diagnosed when a person develops more than 100 adenomatous colon polyps. An adenomatous polyposis is an area where normal cells that line the inside of the colon become mucous and form a mass on the inside of the intestinal tract. The average age for polyps to develop in people with FAP is in the mid-teens. More than 95% of individuals with FAP will have multiple colon polyps by 35 years of age.

Research frontiers
The incidence of FAP is associated with mutations in the q21-q22 region of the long arm of chromosome 5 in 80% of patients. From then onwards, large deletions in the APC gene germline have been reported in families with FAP from different geographic regions. Screening of family members of patients with FAP should begin by 12 years of age. Genetic testing for germline mutations may eliminate the need for surveillance in some family members. Visualization of more than 100 polyps usually establishes the diagnosis because of the diffuse nature of the polyposis.

Treatment
Cancers of the rectum in patients who have had subtotal colectomy with ileorectal anastomosis have been reported with sulindac and celecoxib therapy. Because of the inability to control polyps medically, eventual rectal resection is usually necessary.

Related reports
The mutations found in this study have been extensively described in patients with colorectal malignancies of different ethnic groups and geographic regions, mainly Asian and European populations. This fact reinforces the role of miscegenation in our study population in the appearance of several germline mutations in patients with FAP.

Term explanation
Next-generation sequencing: refers to non-Sanger-based high-throughput DNA sequencing technologies. Millions or billions of DNA strands can be sequenced in parallel, yielding substantially more throughput and minimizing the need for the fragment-cloning methods that are often used in Sanger sequencing of genomes.

Innovations and breakthroughs
FAP is caused by a highly heterogeneous spectrum of mutations, which are shared among patients from different geographic regions. Screening of family members of patients with FAP is a determining factor for clinical guidance and genetic counseling, as well as for simplifying the search for mutations in patients with FAP and their relatives.

Peer-review
The authors found that the c.3956delC mutation is a strong candidate biomarker of this hereditary cancer syndrome in families of northern Brazil. It is noteworthy that different germline mutations were found in families of different ethnic groups. Therefore, there is a need to identify the alterations responsible for hereditary cancer syndromes in the Brazilian population, especially in populations of the northern and northeastern regions, where a high incidence of gastrointestinal tumors is observed.

REFERENCES
1. Pineda M, González S, Lázaro C, Blanco I, Capellá G. Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 2010; 693: 19–31 [PMID: 19931546 DOI: 10.1016/j.mrnam.2009.11.002]
2. Half E, Dercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009; 4: 22 [PMID: 19822006 DOI: 10.1186/1750-1172-4-22]
3. Hosogi H, Nagayama S, Kanamoto N, Yoshizawa A, Suzuki T, Nakao K, Sakai Y. Biallelic APC inactivation was responsible for functional adenocortical adenoma in familial adenomatous polyposis with novel germline mutation of the APC gene: report of a case. Jpn J Clin Oncol 2009; 39: 837-846 [PMID: 19684041 DOI: 10.1093/jjco/hyp093]
4. Palakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997; 1332: F127-F147 [PMID: 9196622 DOI: 10.1016/S0304-419X(97)00008-5]
5. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10: 721-733 [PMID: 11257105 DOI: 10.1093/hmg/10.7.721]
6. Wirmani AK, Rathi A, Sathyaranayana UG, Padar A, Huang CX, Cunningham HT, Farinas AJ, Milichgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001; 7: 1998-2004 [PMID: 11448917]
7. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-5442 [PMID: 10554013]
8. Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. CurrDrug Targets 2014; 15: 90-102 [PMID: 24200292 DOI: 10.2174/138945014666613108155418]
9. Pławska A, Banasiwiez T, Borun P, Kubaszewski L, Krokwicz P, Skrzypeczak-Zielinska M, Lubinski J. Familial adenomatous polyposis of the colon. Hered Cancer Clin Pract 2013; 11: 15 [PMID: 24148210 DOI: 10.1186/1749-8287-11-15]
10. Newton CR, Graham A, Hepstall LE, Powell SJ, Summers C, Kalishker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989; 17: 2503-2516 [PMID: 2785681 DOI: 10.1093/nar/17.7.2503]
11. Bujany DJ, Shea-Simonds J, Reck AC, Finnis D, Eccles DM. Genotype-phenotype correlations of new causative APC gene mutations in patients with familial adenomatous polyposis. J Med Genet 1995; 32: 728-731 [PMID: 8544194]
12. Soravia C, Berk T, Madlensky L, Mitri A, Cheng H, Gallinger S, Cohen Z, Baptz B. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998; 62: 1290-1301 [PMID: 9585611 DOI: 10.1086/301883]
13. Wallis YL, Morton DG, McKeown CM, Macdonald F. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 1999; 36: 14-20 [PMID: 9950360 DOI: 10.1136/jmg.36.1.14]
14. Groves C, Lamlun H, Crabtree M, Williamson J, Taylor C, Basu S, Cuthbert-Heavens D, Hodgson S, Phillips R, Tomlinson I. Mutation cluster region, association between germline and somatic mutations in patients with familial adenomatous polyposis of the colon. J Med Genet 2002; 39: 397 [PMID: 15024739 DOI: 10.1136/jmg.2001.000824]
15. Vandrovcová J, Stekrová J, Kehrlová V, Kohoutová M. Molecular analysis of the APC and MYH genes in Czech families affected by FAP or multiple adenomas: 13 novel mutations. Hum Mutat 2004; 23: 397 [PMID: 15024739 DOI: 10.1002/humu.2224]
16. Nieuwenhuis MH, Vasan HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007; 61: 153-161 [PMID: 17064931 DOI: 10.1016/j.critrevonc.2006.07.004]
17. Silva JAG. Estimate/2012-Cancer Incidence in Brazil. From National Cancer Institute. Rio de Janeiro 2011. Available from: URL: http://www.inca.gov.br/estimativa/2012
2000; 2000; 2011; da Silva FC, Santos EM, Krepischi AC, Achatz 2011; Rodrigues JD, Ribeiro-dos-Santos AK, Poncin J, Arends JW, De Goeij AF. APC mutations 2013; 1994; Jorissen RN, Mouradov D, Sakthianandeswaren A, 2011; 1992; 359: 235-237 2011; 2013; 10: 2081-2088 [PMID: 23970361 DOI: 10.3892/or.2013.2681] 2011; Porto SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 24 2011; 2010; 1967-1979 [PMID: 10784639] 1999; 2009; 42: 870-876 [PMID: 19738982 DOI: 10.1590/S0100- 879X2009000500026] 1999; 42: 271-276 [PMID: 14724163 DOI: 10.1136/gut.2003.015586] 2002; 62: 363-366 [PMID: 11809680] 2003; 2001: 65-156 [PMID: 14961559 DOI: 10.1002/humu.9151] 2001; 870-876 [PMID: 8187091 DOI: 10.1038/359235a0] 2003: 271-276 [PMID: 17542650 DOI: 10.1111/j.1600- 879X.2003.00007.x] 2003: 24085758 DOI: 10.1038/onc.2012.486] 2011; 10: 101 [PMID: 21859464 DOI: 10.1186/1476-4598-10-101] 2000; 82: 348-353 [PMID: 10646887 DOI: 10.1054/ bjoc.1999.0925] 2011; 10: 659-665 [DOI: 10.1007/ s10689-011-9468-4] 1994; 9828834 DOI: 10.1002/(SICI)1096-9896(199808)185: 10-1851 DOI: 10.1002/humu.9151] 2009; 10: 175-180 [PMID: 10378456] 2008; 10784639 [PMID: 1528264 DOI: 10.1038/359235a0] 2003: 655-656 [PMID: 14961559 DOI: 10.1002/humu.9151] 2009; 25: 296-302 [PMID: 21865978 DOI: 10.1097/MPG.0b013e31821986fd] 2008; 57: 704-713 [PMID: 18194984 DOI: 10.1136/gut.2007.136127]
